MCID: MST002
MIFTS: 48

Mast-Cell Leukemia malady

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Mast-Cell Leukemia

Aliases & Descriptions for Mast-Cell Leukemia:

Name: Mast-Cell Leukemia 12 29 14
Leukemia, Mast-Cell 42 69
Leukemia Mast Cell 52

Classifications:



External Ids:

Disease Ontology 12 DOID:9254
ICD10 33 C94.3 C94.30
MeSH 42 D007946
NCIt 47 C3169
UMLS 69 C0023461

Summaries for Mast-Cell Leukemia

Disease Ontology : 12 A leukemia that results_in an overwhelming number of tissue mast cells located in peripheral blood.

MalaCards based summary : Mast-Cell Leukemia, also known as leukemia, mast-cell, is related to aleukemic mast cell leukemia and classic mast cell leukemia. An important gene associated with Mast-Cell Leukemia is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ketamine and Iron have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

Wikipedia : 71 Mast cell leukemia is an extremely aggressive subtype of acute myeloid leukemia that usually occurs de... more...

Related Diseases for Mast-Cell Leukemia

Diseases related to Mast-Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
id Related Disease Score Top Affiliating Genes
1 aleukemic mast cell leukemia 12.2
2 classic mast cell leukemia 12.1
3 systemic mastocytosis 11.4
4 mast-cell sarcoma 11.0
5 leukemia 10.6
6 mastocytosis 10.3
7 intracranial sinus thrombosis 10.2 KIT KITLG
8 uremic neuropathy 10.2 KIT KITLG
9 olfactory nerve disease 10.2 KIT KITLG
10 hemangioma of peripheral nerve 10.2 KIT KITLG
11 high grade b-cell lymphoma with rearrangements of myc and bcl2 and/or bcl6 10.2 KIT KITLG
12 cough variant asthma 10.2 KIT KITLG
13 kidney rhabdoid cancer 10.2 KIT KITLG
14 extranodal nasal nk/t cell lymphoma 10.1 KIT KITLG
15 epidermolysis bullosa simplex, recessive 1 10.1 KIT KITLG
16 diffuse glomerulonephritis 10.1 KIT NTRK3
17 syndromic x-linked intellectual disability 10.1 KIT KITLG
18 steroid dehydrogenase deficiency dental anomalies 10.1 CCL2 CCL5
19 smooth muscle tumor 10.1 CCL2 CCL5
20 bladder signet ring cell adenocarcinoma 10.0 CCL2 CCL5
21 hydrops of gallbladder 10.0 CCL2 CCL5
22 pericoronitis 10.0 KIT KITLG NTRK3
23 gastrointestinal stromal tumor 10.0 KIT KITLG NTRK3
24 myeloid leukemia 10.0
25 popliteal pterygium syndrome, bartsocas-papas type 10.0 KIT NTRK3
26 congenital disorder of glycosylation, type iq 9.9 ITGB1 KIT SYT1
27 mixed mineral dust pneumoconiosis 9.9 CCL2 CCL5
28 may-thurner syndrome 9.9 KIT KITLG NTRK3 RASGRP4
29 mast cell disease 9.9
30 cutaneous mastocytosis 9.9
31 aggressive systemic mastocytosis 9.9
32 asthma 9.7
33 reticulum cell sarcoma 9.7
34 hematopoietic stem cell transplantation 9.7
35 portal hypertension 9.7
36 sarcoma 9.7
37 urticaria pigmentosa 9.7
38 urticaria 9.7
39 histiocytosis 9.7
40 sm-ahnmd 9.7
41 monocytic leukemia 9.7
42 back pain 9.7
43 acute basophilic leukemia 9.7
44 priapism 8.8 BTK CCL2 CCL5 ITGB1 KIT KITLG

Graphical network of the top 20 diseases related to Mast-Cell Leukemia:



Diseases related to Mast-Cell Leukemia

Symptoms & Phenotypes for Mast-Cell Leukemia

GenomeRNAi Phenotypes related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.8 SYT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.8 BTK KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.8 SYT1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.8 BTK
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.8 SYT1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.8 NTRK3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.8 BTK NTRK3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.8 BTK
9 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.8 NTRK3 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.8 KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.8 SYT1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.8 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.8 SYT1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.8 BTK
15 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.8 NTRK3 KIT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.8 BTK
17 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.8 NTRK3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.8 NTRK3 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.8 BTK
20 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.8 SYT1 BTK KIT NTRK3
21 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.8 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.8 KIT

MGI Mouse Phenotypes related to Mast-Cell Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.8 BTK CCL5 ITGB1 KIT KITLG RASGRP4
2 digestive/alimentary MP:0005381 9.77 ITGB1 KIT KITLG RASGRP4 BTK
3 immune system MP:0005387 9.7 BTK CCL2 CCL5 ITGB1 KIT KITLG
4 hearing/vestibular/ear MP:0005377 9.62 ITGB1 KIT KITLG NTRK3
5 pigmentation MP:0001186 9.26 ITGB1 KIT KITLG RASGRP4
6 vision/eye MP:0005391 9.02 ITGB1 KIT KITLG NTRK3 RASGRP4

Drugs & Therapeutics for Mast-Cell Leukemia

Drugs for Mast-Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
3
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
4
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
5
Cyproheptadine Approved Phase 3 129-03-3 2913
6
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
7 Analgesics Phase 3,Phase 2
8 Neurotransmitter Agents Phase 3
9 Anesthetics Phase 3
10 Anesthetics, Dissociative Phase 3
11 Anesthetics, General Phase 3
12 Anesthetics, Intravenous Phase 3
13 Peripheral Nervous System Agents Phase 3,Phase 2
14 Excitatory Amino Acid Antagonists Phase 3
15 Excitatory Amino Acids Phase 3
16 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
17 ferric gluconate Phase 3
18 Narcotics Phase 3
19 Hematinics Phase 3,Phase 2
20 Dermatologic Agents Phase 3,Phase 2,Phase 1
21 Analgesics, Opioid Phase 3
22 Ferric Compounds Phase 3
23
Histamine Phosphate Phase 3 51-74-1 65513
24
Serotonin Phase 3 50-67-9 5202
25 Serotonin Agents Phase 3
26 Serotonin Antagonists Phase 3
27 Gastrointestinal Agents Phase 3
28 Histamine Antagonists Phase 3
29 Histamine H1 Antagonists Phase 3
30 Anti-Allergic Agents Phase 3
31 Antipruritics Phase 3
32 Iron Supplement Nutraceutical Phase 3
33
Sunitinib Approved, Investigational Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
34
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
35
Cyclosporine Approved, Investigational, Vet_approved Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
36
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
37
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
38
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
39
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
40
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
41
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
42
Vidarabine Approved Phase 2,Phase 1 24356-66-9 32326 21704
43
Busulfan Approved, Investigational Phase 2 55-98-1 2478
44
rituximab Approved Phase 2 174722-31-7 10201696
45
Bortezomib Approved, Investigational Phase 1, Phase 2,Early Phase 1 179324-69-7 387447 93860
46
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
47
alemtuzumab Approved, Investigational Phase 2 216503-57-0
48
Denileukin diftitox Approved, Investigational Phase 2 173146-27-5
49
Levoleucovorin Approved Phase 2 68538-85-2
50
leucovorin Approved, Nutraceutical Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143

Interventional clinical trials:

(show top 50) (show all 57)
id Name Status NCT ID Phase
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
2 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
3 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
4 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
5 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
6 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
7 Midostaurin in Indolent Systemic Mastocytosis Unknown status NCT01920204 Phase 2
8 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2
9 Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD Completed NCT00186628 Phase 2
10 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2
11 Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Completed NCT00493129 Phase 2
12 Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer Completed NCT00627666 Phase 2
13 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2
14 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2
15 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
16 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2
17 Stem Cell Transplantation to Treat Systemic Mastocytosis Completed NCT00006413 Phase 2
18 Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Recruiting NCT02415608 Phase 2
19 Phase II Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia Active, not recruiting NCT00233454 Phase 2
20 Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia Active, not recruiting NCT00782067 Phase 2
21 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2
22 Sunitinib in Treating Patients With Idiopathic Myelofibrosis Terminated NCT00387426 Phase 2
23 Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Withdrawn NCT01101412 Phase 1, Phase 2
24 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1
25 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1
26 Quality of Life in Younger Leukemia and Lymphoma Survivors Completed NCT00956475 Phase 1
27 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies Recruiting NCT02561988 Phase 1
28 Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer Recruiting NCT01137643 Phase 1
29 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Recruiting NCT02571036 Phase 1
30 Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Unknown status NCT00897767
31 Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy Unknown status NCT00670917
32 Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer Unknown status NCT01295463
33 Patient-Reported Outcome Questionnaire for Systemic Mastocytosis Completed NCT02380222
34 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Completed NCT00112593
35 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766
36 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Completed NCT01199562
37 S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers Completed NCT00996047
38 Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial Completed NCT00890435
39 Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone Completed NCT00993694
40 Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases Completed NCT00376922
41 Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders Completed NCT00437086 Early Phase 1
42 Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Recruiting NCT01807598
43 Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia Recruiting NCT01869777
44 Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Recruiting NCT00898079
45 Mast Cell Connect: A Registry for Patients With Mastocytosis Recruiting NCT02620254
46 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer Recruiting NCT00935090
47 Registry of Older Patients With Cancer Recruiting NCT01137825
48 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer Active, not recruiting NCT01053494
49 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies Active, not recruiting NCT00014235
50 Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases Active, not recruiting NCT00424242 Early Phase 1

Search NIH Clinical Center for Mast-Cell Leukemia

Cochrane evidence based reviews: leukemia, mast-cell

Genetic Tests for Mast-Cell Leukemia

Genetic tests related to Mast-Cell Leukemia:

id Genetic test Affiliating Genes
1 Mast Cell Leukemia 29

Anatomical Context for Mast-Cell Leukemia

MalaCards organs/tissues related to Mast-Cell Leukemia:

39
Myeloid, Bone, Bone Marrow, Monocytes

The Foundational Model of Anatomy Ontology organs/tissues related to Mast-Cell Leukemia:

18
Peripheral Blood

Publications for Mast-Cell Leukemia

Articles related to Mast-Cell Leukemia:

(show top 50) (show all 63)
id Title Authors Year
1
A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data. ( 27104187 )
2016
2
Application of next generation sequencing in the diagnosis and management of mast cell leukemia. ( 27104182 )
2016
3
Extramedullary Involvement of Mast Cell Leukemia Detected by 18F-FDG PET/CT. ( 26975014 )
2016
4
Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia. ( 26876592 )
2016
5
Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. ( 25443885 )
2015
6
De novo leukemic variant of mast cell leukemia with KIT D816V. ( 25729733 )
2015
7
Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. ( 26055303 )
2015
8
Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. ( 25209843 )
2014
9
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. ( 24675021 )
2014
10
Mast cell leukemia: an extremely rare disease. ( 25028296 )
2014
11
Mast cell leukemia with prolonged survival on PKC412/midostaurin. ( 25031773 )
2014
12
Mast cell leukemia associated with undefined morphology and chronic basophilic leukemia. ( 25264491 )
2014
13
FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. ( 24596674 )
2014
14
The transcriptome of the human mast cell leukemia cells HMC-1.2: an approach to identify specific changes in the gene expression profile in KitD816V systemic mastocytosis. ( 23504229 )
2013
15
Mast cell leukemia. ( 23243287 )
2013
16
A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation. ( 23483057 )
2013
17
A case of de novo aleukemic mast cell leukemia without c-KIT mutations in exons 8 and 17. ( 24034180 )
2013
18
Sustained paranoid psychosis in a patient with mast cell leukemia and decreased serotonin level. ( 23793328 )
2013
19
Death from mast cell leukemia: a young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia. ( 22329485 )
2012
20
Aleukemic variant of mast cell leukemia. ( 22482127 )
2012
21
Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor I^ chain and KIT V654A. ( 22173243 )
2012
22
Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. ( 22324351 )
2012
23
Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm. ( 22661384 )
2012
24
Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. ( 21261503 )
2011
25
The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). ( 20688965 )
2010
26
Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. ( 20485374 )
2010
27
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. ( 20658589 )
2010
28
Mast cell leukemia with rapidly progressing portal hypertension. ( 19883434 )
2009
29
KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. ( 17949810 )
2008
30
Mast cell leukemia: a report of ten cases. ( 18172645 )
2008
31
Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia. ( 16543062 )
2006
32
Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia. ( 15928938 )
2005
33
Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated H-Ras. ( 15735740 )
2005
34
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. ( 15972446 )
2005
35
Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V. ( 15512820 )
2004
36
Mast cell leukemia. ( 12564414 )
2003
37
Malignant hematopoietic cell lines: in vitro models for the study of mast cell leukemia. ( 12801523 )
2003
38
Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation. ( 12815487 )
2003
39
Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs. ( 12688323 )
2003
40
Low back pain and myalgias in acute and relapsed mast cell leukemia: a case report. ( 12048668 )
2002
41
Mast cell leukemia--a rare form of myeloid leukemia. ( 12238304 )
2002
42
RasGRP4, a new mast cell-restricted Ras guanine nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. Identification of defective variants of this signaling protein in asthma, mastocytosis, and mast cell leukemia patients and demonstration of the importance of RasGRP4 in mast cell development and function. ( 11956218 )
2002
43
Synaptotagmin I expression in mast cells of normal human tissues, systemic mast cell disease, and a human mast cell leukemia cell line. ( 11181737 )
2001
44
Connective tissue-type mast cell leukemia in a dog. ( 10720189 )
2000
45
Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. ( 10072109 )
1999
46
Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. ( 9149916 )
1997
47
Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. ( 7512180 )
1994
48
Expression of multiple chemokine genes by a human mast cell leukemia. ( 8188667 )
1994
49
Identification of mutations in the coding sequence of the proto- oncogene c-kit in a human mast cell leukemia cell line causing ligand- independent activation of c-kit product. ( 7691885 )
1993
50
Porcine mast cell leukemia with systemic mastocytosis. ( 2492400 )
1989

Variations for Mast-Cell Leukemia

ClinVar genetic disease variations for Mast-Cell Leukemia:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 KIT NM_000222.2(KIT): c.2447A> T (p.Asp816Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913507 GRCh37 Chromosome 4, 55599321: 55599321

Expression for Mast-Cell Leukemia

Search GEO for disease gene expression data for Mast-Cell Leukemia.

Pathways for Mast-Cell Leukemia

Pathways related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.71 BTK CCL2 CCL5 ITGB1 KIT KITLG
2
Show member pathways
13.47 BTK CCL2 CCL5 ITGB1 KIT KITLG
3
Show member pathways
13.32 BTK CCL2 CCL5 KIT KITLG NTRK3
4
Show member pathways
12.94 BTK CCL2 CCL5 ITGB1 KIT KITLG
5
Show member pathways
12.91 CCL2 CCL5 ITGB1 KIT KITLG RASGRP4
6
Show member pathways
12.8 BTK CCL2 CCL5 KIT KITLG NTRK3
7
Show member pathways
12.77 CCL2 KIT KITLG NTRK3
8
Show member pathways
12.66 BTK ITGB1 KIT KITLG NTRK3
9
Show member pathways
12.65 BTK CCL2 CCL5 ITGB1 KIT KITLG
10
Show member pathways
12.61 BTK ITGB1 KIT KITLG
11
Show member pathways
12.37 ITGB1 KIT KITLG RASGRP4
12 12.3 ITGB1 KIT KITLG RASGRP4
13
Show member pathways
11.91 BTK KIT KITLG
14 11.82 BTK KIT KITLG
15 11.52 BTK CCL2 CCL5 KIT KITLG
16 11.3 CCL2 CCL5
17 11.28 KIT KITLG
18 11.2 KIT KITLG
19 11.16 CCL5 ITGB1
20 11.05 CCL5 ITGB1
21 10.94 BTK CCL2 CCL5
22 10.68 KIT KITLG

GO Terms for Mast-Cell Leukemia

Cellular components related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.28 BTK CCL2 CCL5 ITGB1 KIT KITLG
2 mast cell granule GO:0042629 8.96 BTK KIT

Biological processes related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.9 BTK CCL2 KIT NTRK3
2 positive regulation of cell proliferation GO:0008284 9.85 ITGB1 KIT KITLG NTRK3
3 positive regulation of cell migration GO:0030335 9.75 CCL5 KIT NTRK3
4 protein autophosphorylation GO:0046777 9.74 BTK KIT NTRK3
5 peptidyl-tyrosine phosphorylation GO:0018108 9.73 BTK KIT NTRK3
6 positive regulation of cell adhesion GO:0045785 9.64 CCL2 CCL5
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.64 CCL5 KIT
8 visual learning GO:0008542 9.63 ITGB1 KIT
9 ovarian follicle development GO:0001541 9.63 KIT KITLG
10 monocyte chemotaxis GO:0002548 9.62 CCL2 CCL5
11 protein kinase B signaling GO:0043491 9.62 CCL2 CCL5
12 lipopolysaccharide-mediated signaling pathway GO:0031663 9.61 CCL2 CCL5
13 cellular response to fibroblast growth factor stimulus GO:0044344 9.61 CCL2 CCL5
14 response to tumor necrosis factor GO:0034612 9.59 CCL2 CCL5
15 leukocyte cell-cell adhesion GO:0007159 9.58 CCL5 ITGB1
16 positive regulation of Ras protein signal transduction GO:0046579 9.54 KITLG RASGRP4
17 positive regulation of JAK-STAT cascade GO:0046427 9.52 CCL5 KIT
18 positive regulation of synaptic transmission GO:0050806 9.51 CCL2 SYT1
19 positive regulation of monocyte chemotaxis GO:0090026 9.49 CCL2 CCL5
20 embryonic hemopoiesis GO:0035162 9.48 KIT KITLG
21 positive regulation of macrophage chemotaxis GO:0010759 9.46 CCL2 CCL5
22 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.46 BTK KIT NTRK3 RASGRP4
23 positive regulation of leukocyte migration GO:0002687 9.43 CCL2 KITLG
24 cell chemotaxis GO:0060326 9.43 CCL2 CCL5 KIT
25 macrophage chemotaxis GO:0048246 9.4 CCL2 CCL5
26 germ cell migration GO:0008354 9.37 ITGB1 KIT
27 MAPK cascade GO:0000165 9.35 CCL2 CCL5 KIT KITLG RASGRP4
28 ectopic germ cell programmed cell death GO:0035234 9.32 KIT KITLG
29 positive regulation of GTPase activity GO:0043547 9.1 CCL2 CCL5 ITGB1 KIT KITLG RASGRP4

Molecular functions related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 CCL2 CCL5 KITLG
2 protein tyrosine kinase activity GO:0004713 9.33 BTK KIT NTRK3
3 chemokine activity GO:0008009 9.32 CCL2 CCL5
4 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.13 KIT KITLG RASGRP4
5 protein kinase activity GO:0004672 9.02 BTK CCL2 CCL5 KIT NTRK3

Sources for Mast-Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....